Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review
Authors' conclusion
In our study, SAR exhibited encouraging efficacy in stabilising RA-ILD in most cases.
Study context
- Population
- Rheumatoid arthritis (RA) patients with interstitial lung disease (ILD) from the KEIO-RA cohort treated with sarilumab (SAR), 2018–2024; median age 56 years, 71.4% female21 (17.1%) with ILD
- Participants
- 123 patients
- Outcome
- Rate of progression of ILD assessed by HRCT
- Follow-up
- 24 months
Methodological detailsconsecutive patients, single-centre, literature review
- Consecutive patients
- Single-centre
- Literature review
Main finding
As reported in the abstract
Stable HRCT findings during SAR
SAR
85.7%
18 of 21
- Improvement in both high-resolution computed tomography (HRCT) findings and arthritis (NSIP and OP patterns)
- 2
- Exacerbation of ILD at 18 months, preceded by worsening arthritis
- 1
Observational data: associations, not effects.
Further findings
Serum KL-6
- Improved or remained stable after SAR initiation, except in one case of ILD exacerbation
Literature review
- One case of RA-ILD treated with SAR achieved remission of arthritis and ILD
Safety
Adverse events, including serious infections, during observation · 24 months
- No adverse events, including serious infections, during the observation period
Original publication
Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review. Clin Exp Rheumatol. Published 28 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →